 NEW YORK, Dec. 01, 2022 GLOBE NEWSWIRE Y-mAbs Therapeutics, Inc. the Company or Y-mAbs Nasdaq: YMAB a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S. Food and Drug Administration FDA has issued a complete response letter CRL for ... The post Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application ap... 